Vaccinia
diseaseOn this page
Summary
Vaccinia (MONDO:0002595) is a disease and 7 clinical trials. Top therapeutic interventions include human papillomavirus, l1 protein virus like particles and tecovirimat. A subtype of viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 7
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | vaccinia |
| Mondo ID | MONDO:0002595 |
| MeSH | D014615 |
| DOID | DOID:3298 |
| ICD-11 | 1275065853 |
| SNOMED CT | 111852003 |
| UMLS | C0042214 |
| MedGen | 52964 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of viral infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › vaccinia
Related subtypes (40): Whitewater Arroyo hemorrhagic fever, exanthema subitum, Zika virus congenital syndrome, common wart, viral labyrinthitis, viral gastritis, viral esophagitis, Kaposi’s sarcoma, contagious pustular dermatitis, epidemic pleurodynia, herpangina, human T-lymphotropic virus 1 infectious disease, lumpy skin disease, milker’s nodule, molluscum contagiosum, Newcastle disease, pharyngoconjunctival fever, pseudorabies, Reoviridae infectious disease, immunodeficiency 32B, focal epithelial hyperplasia, neurolymphomatosis, viral myositis, virus-associated trichodysplasia spinulosa, infective dermatitis associated with HTLV-1, congenital varicella syndrome, viral hemorrhagic fever, arbovirus fever, human infection by orthopoxvirus, congenital Epstein-Barr virus infection, rabies, arbovirus infection, viral eye infection, viral infection of central nervous system, viral respiratory tract infection, Parvoviridae infectious disease, COVID-19–associated multisystem inflammatory syndrome in children, primary viral infectious disease, disease arising from reactivation of latent virus, human betaherpesvirus 5 infectious disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE2 | 1 |
| PHASE1 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00081835 | PHASE2 | COMPLETED | Evaluation and Treatment of Eye Complications of Vaccinia Vaccination |
| NCT00303225 | PHASE1 | WITHDRAWN | SIGA-246 to Treat Smallpox |
| NCT06366672 | EARLY_PHASE1 | ACTIVE_NOT_RECRUITING | Evaluating the Human Immune Response to the JYNNEOS Vaccine |
| NCT06616753 | Not specified | RECRUITING | Evaluation of Patients’ Knowledge of Their Vaccination Status and Their Relationship to Vaccination at Melun Hospital |
| NCT04022148 | Not specified | UNKNOWN | The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years |
| NCT05092568 | Not specified | UNKNOWN | Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service |
| NCT06650722 | Not specified | COMPLETED | Evaluation of Healthcare Workers Knowledge Regarding Their Vaccination Status at Melun Hospital |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES | 4 | 1 |
| TECOVIRIMAT | 4 | 1 |